Navigation Links
Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc.
Date:7/14/2014

San Francisco, Calif., July 14, 2014 /PRNewswire/ -- Synthetic biology company Pareto Biotechnologies today announces a technology partnership with global bioengineering leader DNA2.0, enabling Pareto to further develop its technology for quick-to-market products.

The integration of Pareto's rational-based design approach and DNA2.0's machine learning optimization technologies, such as ProteinGPS™ and GeneGPS™, is drastically speeding up the process of engineering proteins in the Pareto pipeline. Specifically, Pareto will merge its novel synthetic biology platform with DNA2.0's ProteinGPS™ engineering technology, to identify and quantify genetic mutations to be incorporated into iterative rounds of improved synthetic genes. The tool rapidly generates proteins with improved characteristics.

"Rational-based design has been the core of my life's work. The marriage of Pareto's novel platform with DNA2.0's engineering expertise will create fantastic opportunities for enhancing enzymes for the production of Pareto products," said Dr. Joseph Noel, Salk Institute for Biological Studies Professor and Chairman of Pareto Biotechnologies' Scientific Advisory Board.

Pareto's CEO, Jamie Bacher, continued, "Our deep understanding of the structures of these classes of enzymes, along with a statistical optimization algorithm from DNA2.0 gets us the best of both worlds: rational design and robust enzyme improvement. Through our relationship with DNA2.0, we'll be able to generate completely novel molecules with applicability to flavors and fragrances, cosmetics, and therapeutics."

The broad applicability of this combined approach enables a progressive application of the technology along the value chain, as a practical demonstration of the power of market-driven research and development efforts – a.k.a. "Synthetic Biology 2.0." Pareto will leverage DNA2.0's specific technologies to increase the efficacy of its own platform to generate flavors, fragrances and cosmetics with improved and novel properties. As the technology is further developed, it will also enhance drug discovery platforms, as well as the generation of industrial chemicals.

"Our patented bioengineering approaches, especially ProteinGPS™ and GeneGPS™, have been validated by many scientific publications and successful partners. Recently we published a seminal ProteinGPS paper in ACS Synthetic Biology. The technology allows the researcher to engineer any biological function using only a few hundred samples. We are delighted to partner with Pareto and Dr. Joe Noel in their exciting endeavor to ignite the molecular revolution," said Claes Gustafsson, DNA2.0's Chief Commercial Officer.

About Pareto Biotechnologies:
Pareto Biotechnologies is a synthetic biology startup that is poised to lead the movement towards a bio-based economy. Pareto's platform fully leverages its dominant IP position in polyketide pathways, combining structurally-guided enzyme design and synthetic biology to develop a platform for designer molecules with broad applicability: cosmetics, flavors, fragrances, therapeutics, industrial commodity chemicals, and chemical intermediates. Learn More About Pareto Biotechnologies.

About DNA2.0:
DNA2.0 is the leading bioengineering solutions provider, offering an integrated pipeline of solutions, including gene design, optimization, synthesis, and platforms for protein and strain engineering. DNA2.0 explores novel applications for synthetic genes and the synergy between efficient gene design and protein optimization technologies. DNA2.0's tools and solutions are fueling the transformation of biology from a discovery science to an engineering discipline. Learn More About DNA2.0.

Media Contact:
Kristen Caron
Kristen@7SecondStrategies.com 
978-407-9283


'/>"/>
SOURCE Pareto Biotechnologies
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
2. Medical Marijuana Inc. Portfolio Company CanChew BioTechnologies Inc. Announces Final Three Days for Market Survey and Free Product Trial Registration
3. Lifeline Biotechnologies Receives Third Software Patent
4. Lifeline Biotechnologies First Warning Systems
5. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
6. ISSI Announces Fiscal 2014 Third Quarter Conference Call
7. CVS Caremark Corporation Announces Quarterly Dividend
8. Sono-Tek Announces Third Quarter Results
9. Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
10. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
11. Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... 24, 2017 IBM (NYSE: IBM ) has ... for Solid-State Arrays (SSA) for the fourth year in a ... to Gartner, "Vendors in the Leaders quadrant have the highest ... A vendor in the Leaders quadrant has the market share, ... acceptance of new technologies. These vendors demonstrate a clear understanding ...
(Date:7/21/2017)... Did you know that PhRMA member companies invested $65.5 ... spending on brand medicines, generics and the supply chain account for ... just half of this (7 percent)? Or that the ... venture capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical ...
(Date:7/14/2017)... 14, 2017 Endo International plc (NASDAQ: ENDP ... 8, 2017.  Members of its senior management team will host a ... 8:30 a.m. ET. The dial-in number to access ... (678) 509-7598, and the passcode is 45397076. Please dial in 10 ... A replay of the call will be available ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... ... provider in the United States, today announced its partnership with financial technology company, ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Engineers at the ... because it produces the same kind of electrical energy that the body uses. ... of moving electrons. This flow of electrons out of the battery is generated by ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 2017 , ... Every year, thousands of dedicated Higher Education and K12 professionals ... is coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs ...
(Date:7/24/2017)... Solana Beach, California (PRWEB) , ... July 24, ... ... and commercialization of autologous fat (adipose) transfer systems announces the issuance of United ... (the ‘324 patent) for its adipose filtration technology. The '398 and '324 ...
Breaking Medicine News(10 mins):